FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,276 letters match. Newest first.

  1. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  2. Azurity Pharmaceuticals, Inc.

    FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.

    High risk
  3. Nomida.biz

    FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.

    High risk
  4. Accupack Midwest, Inc.

    Accupack Midwest, an over-the-counter drug contract manufacturer, lacked adequate water controls and process validation.

    High risk
  5. Wittman Pharma, Inc.

    FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.

    High risk
  6. Aerosol and Liquid Packaging, Inc.

    FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.

    High risk
  7. Quality CDMO, Inc.

    FDA warned Quality CDMO that its prescription skin and scalp drugs are unapproved and lack FDA-approved applications.

    High risk
  8. Aromas Para El Alma S.A.

    Aromas Para El Alma, a Costa Rica drug manufacturer, made EREWHON hand sanitizer/spray subpotent and broke manufacturing rules.

    High risk
  9. EnviroServe Chemicals & Cleaners Ltd.

    EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.

    High risk
  10. Greco Gas, Inc.

    Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.

    High risk
  11. TJA Health, LLC

    FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.

    High risk
  12. Avaria Health & Beauty Corp.

    FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.

    High risk
  13. Root Bioscience Brands, LLC dba Naternal

    FDA warned Naternal that its CBD oils, gummies, and pet hemp oil are unapproved drugs due to drug claims.

    High risk
  14. Zydus Lifesciences Limited

    FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.

    High risk
  15. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  16. Regenerative Processing Plant, LLC

    FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.

    High risk
  17. MexHealth LLC d/b/a Al Natural E-Shop

    FDA warned MexHealth LLC d/b/a Al Natural E-Shop that its Ossos-Sans supplement is an unapproved, misbranded drug containing hidden diclofenac and methocarbamol.

    High risk
  18. SoloVital

    FDA says SoloVital's Umary supplement is an unapproved, misbranded drug containing hidden diclofenac and omeprazole.

    High risk
  19. Everymarket Inc.

    FDA warned Everymarket Inc. that its website sells two unapproved drugs, one with hidden dexamethasone and chlorpheniramine.

    High risk
  20. Julio R. Flamini, M.D./Clinical Integrative Research Center of Atlanta

    FDA warns an Atlanta clinical investigator after a 15-year-old trial subject was given about 10 times the protocol dose.

    High risk
  21. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  22. AnuMed International, LLC

    FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.

    High risk
  23. CARsgen Therapeutics Corporation

    FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.

    High risk
  24. EyePoint Pharmaceuticals, Inc.

    FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.

    High risk
  25. Media Networks Sydney Pty Limited

    Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.

    Low
  26. Eugia Pharma Specialities Limited

    FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.

    High risk
  27. Intercos Europe S.p.A

    FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.

    High risk
  28. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  29. Nowrez & Ismail Shukri Company

    FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.

    High risk
  30. Central Admixture Pharmacy Services, Inc.

    FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.

    High risk
  31. Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.

    FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.

    High risk
  32. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  33. Velocity Pharma LLC

    Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

    High risk
  34. Walmart, Inc.

    FDA warned Walmart over selling an unapproved 90% lactic acid chemical peel drug that can cause burns.

    High risk
  35. ISIS.GOLD

    ISIS.GOLD sells TCA 100% and Whitening SA chemical peels as unapproved new drugs without FDA-approved applications.

    High risk
  36. Skin Beauty Solutions

    FDA warns Skin Beauty Solutions that its chemical peel products are unapproved new drugs sold with acne and scar treatment claims.

    High risk
  37. Repare Skincare

    Repare Skincare sold unapproved TCA and glycolic acid chemical peels online with drug claims, FDA says.

    High risk
  38. Matte Beauty

    FDA warned Matte Beauty that its chemical peel drugs are unapproved and sold with treatment claims.

    High risk
  39. Amazon.com, Inc.

    FDA warns Amazon over selling two unapproved chemical peel drugs that can burn skin.

    High risk
  40. V10Suppliers.com

    FDA warned UK website V10Suppliers.com for selling unapproved, misbranded opioid drugs to U.S. consumers.

    High risk
  41. Brassica Pharma Pvt. Ltd.

    FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.

    High risk
  42. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  43. Yahon Enterprise Co., Ltd.

    FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.

    High risk
  44. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

    FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.

    High risk
  45. Cholrem Pty Ltd dba Cholrem and Cholrem Pharmaceuticals

    FDA warned Cholrem over selling unapproved RemChol enema products with claims to treat atherosclerosis and reverse heart disease.

    High risk
  46. YangZhou SuXiang Medical Instrument Co., Ltd.

    FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.

    High risk
  47. Max Chemical Inc.

    FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.

    High risk
  48. ARG Laboratories, Inc.

    FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

    High risk
  49. Art of Beauty Company, Inc.

    FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.

    High risk
  50. reBom Co., Ltd.

    reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.

    High risk